What disease areas does myTomorrows cover?

raymond.vanderwaal@mytomorrows.com 12 Jan 2024

1 mins read

share this post

myTomorrows supports a wide range of therapeutic areas, offering patient recruitment solutions across various medical fields. Whether your clinical trial is focused on oncology, rare diseases, hematology, neurology, or any other therapeutic area, we have the expertise to assist in patient recruitment, pre-screening, and referrals to clinical trials.

share this post

raymond.vanderwaal@mytomorrows.com 12 Jan 2024

more articles

view all blogs
Woman with Multiple System Atrophy using a cane to walk
Neurological disorders
Multiple System Atrophy
MSA Symptoms

Exploring the Symptoms of Multiple System Atrophy

Andrea Enguita

13 Aug 2025

15 mins read

James Griffin sickle cell patient advocate
patient advocacy
Sickle Cell Anemia

Treatment Advances and Patient Advocacy in Sickle Cell Disease: A Conversation with James Griffin

John Massarelli

7 Aug 2025

10 mins read

Survey Research
Physicians
Clinical Trials
AI
Trial Access

Searching for Solutions: How Physicians Navigate Trial Access and Technology

Michel van Harten

17 Jul 2025

4 mins read

Older woman walking with the help of a walker
Clinical Research
Investigational treatments
Neurological disorders
Multiple System Atrophy

Multiple System Atrophy: Understanding the Condition

Andrea Enguita

23 Jun 2025

15 mins read

Clinical Trials
AI
Patients

myTomorrows Surpasses 15,000 Patient Matches through AI-Powered Platform and Personalized Services

myTomorrows Team

20 May 2025

3 mins read

Scout clinical & myTomorrows partnership
Clinical Trials
Clinical Trial Recruitment
Partnership

myTomorrows and Scout Clinical Partner to Provide Cross-Border Patient Recruitment for Clinical Trials

myTomorrows Team

15 Apr 2025

4 mins read

Man with Parkinson's being helped by a caregiver
Parkinson's disease
Neurological disorders
Investigational treatments
Clinical Research

Parkinson’s Disease Explained: From Early Symptoms to Latest Research

Andrea Enguita

11 Apr 2025

20 mins read